title: Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study.
abstract: In this study, the authors investigated the physiologic effects of the altered body composition that results from surgical removal of large amounts of subcutaneous adipose tissue. Fourteen women with body mass indexes of greater than > 27 kg/m2 underwent measurements of fasting plasma insulin, triglycerides, cholesterol, body composition by dual-energy x-ray absorptiometry (DXA), resting energy expenditure, and blood pressure before and after undergoing large-volume ultrasound-assisted liposuction. There were no significant intraoperative complications. Body weight had decreased by 5.1 kg (p < 0.0001) by 6 weeks after liposuction, with an additional 1.3-kg weight loss (p < 0.05) observed between 6 weeks and 4 months after surgery, for a total weight loss of 6.5 kg (p < 0.00006). Body mass index decreased from (mean +/- SEM) 28.8 +/- 2.3 to 26.8 +/- 1.5 kg/m2 (p < 0.0001). This change in body weight was primarily the result of decreases in body fat mass: as assessed by DXA, lean body mass did not change (43.8 +/- 3.1 kg to 43.4 +/- 3.6 kg, p = 0.80), whereas DXA total body fat mass decreased from 35.7 +/- 6.3 to 30.1 +/- 6.5 kg (p < 0.0001). There were significant decreases in fasting plasma insulin levels (14.9 +/- 6.5 mIU/ml before liposuction versus 7.2 +/- 3.2 mIU/ml 4 months after liposuction, p < 0.007), and systolic blood pressure (132.1 +/- 7.2 versus 120.5 +/- 7.8 mmHg, p < 0.0002). Total cholesterol, high-density lipoprotein cholesterol, plasma triglycerides, and resting energy expenditure values were not significantly altered after liposuction. In conclusion, over a 4-month period, large-volume liposuction decreased weight, body fat mass, systolic blood pressure, and fasting insulin levels without detrimental effects on lean body mass, bone mass, resting energy expenditure, or lipid profiles. Should these improvements be maintained over time, liposuction may prove to be a valuable tool for reducing the comorbid conditions associated with obesity.
authors.affiliation: Georgetown University, Washington, DC, USA. www.drsharongiese.com
authors.forename: S Y
authors.initials: SY
authors.lastname: Giese
authors.forename: E J
authors.initials: EJ
authors.lastname: Bulan
authors.forename: G W
authors.initials: GW
authors.lastname: Commons
authors.forename: S L
authors.initials: SL
authors.lastname: Spear
authors.forename: J A
authors.initials: JA
authors.lastname: Yanovski
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D001481:Basal Metabolism; D001794:Blood Pressure; D001823:Body Composition; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D015187:Lipectomy; D008055:Lipids / Q000097:blood; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D010865:Pilot Projects; D012307:Risk Factors; D015431:Weight Loss
chemical_list: D007328:Insulin; D008055:Lipids